ARQL stock forecast
Our latest prediction for ArQule, Inc.'s stock price was made on the May 30, 2018 when the stock price was at 4.73$.
In the short term (2weeks), ARQL's stock price should underperform the market by -1.76%. During that period the price should oscillate between -13.56% and +21.03%.
In the medium term (3months), ARQL's stock price should outperform the market by 1.11%. During that period the price should oscillate between -26.38% and +51.44%.Get email alerts
About ArQule, Inc.
ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.
At the moment the company generates 23M USD in revenues.
On its last earning announcement, the company reported a loss of -0.16$ per share.
The book value per share is 0.25$
Three months stock forecastMay 30, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|